SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
August 13, 2001
Date of Report (Date of earliest event reported)
GERON CORPORATION
(Exact name of registrant as specified in its charter)
Delaware (State or Other Jurisdiction of Incorporation) |
0-20859 (Commission File Number) |
75-2287752 (IRS Employer Identification Number) |
||
230 Constitution Drive Menlo Park, California (Address of principal executive offices) |
94025 (Zip Code) |
(650) 473-7700
(Registrants telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events. | ||||||||
Item 7. Exhibits. | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
EXHIBIT 99.1 |
Item 5. Other Events.
On August 13, 2001, the Registrant publicly disseminated a press release and backgrounder announcing that Kyowo Hakko Kogyo Co., Ltd. had selected a telomerase inhibitor compound for the treatment of cancer. The compound (GRN163) is a short, modified oligonucleotide designed as a telomerase template antagonist. The compound shows good bioavailability and binds specifically to the active site of telomerase, thereby blocking its activity in cancer cells.
The foregoing description is qualified in its entirety by reference to the Registrants Press Release and Backgrounder dated August 13, 2001, copies of which are attached hereto as Exhibit 99.1.
Item 7. Exhibits.
Exhibits | ||||||
99.1 | Press Release and Backgrounder dated August 13, 2001. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GERON CORPORATION | ||
Date: August 22, 2001 | By: | /s/ David L. Greenwood |
Name: | David L. Greenwood | |
Title: | Senior Vice President and Chief Financial Officer |
3
EXHIBIT INDEX
Exhibits | ||||||
99.1 | Press Release and Backgrounder dated August 13, 2001. |